Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Chimeric Antigen Receptor T Cell-Related Neurotoxicity: Mechanisms, Clinical Presentation, and Approach to Treatment
Jessica Rice, Sarah Nagle, Julie Randall, et al.
Current Treatment Options in Neurology (2019) Vol. 21, Iss. 8
Closed Access | Times Cited: 83

Showing 26-50 of 83 citing articles:

EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations
Isabelle Beuchat, Husain Danish, Daniel B. Rubin, et al.
Neuro-Oncology (2021) Vol. 24, Iss. 2, pp. 313-325
Open Access | Times Cited: 26
Mechanisms of immune effector cell‐associated neurotoxicity syndrome after CAR‐T treatment
Tianning Gu, Kejia Hu, Xiaohui Si, et al.
WIREs Mechanisms of Disease (2022) Vol. 14, Iss. 6
Open Access | Times Cited: 18
Development and validation of a patient‐reported outcome measure to assess symptom burden after chimeric antigen receptor T‐cell therapy
Xin Shelley Wang, Samer A. Srour, Tito R. Mendoza, et al.
British Journal of Haematology (2023) Vol. 201, Iss. 4, pp. 738-746
Closed Access | Times Cited: 10
Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment
Gede Kambayana, Sandra Surya Rini
Current Rheumatology Reviews (2023) Vol. 19, Iss. 3, pp. 260-269
Closed Access | Times Cited: 10
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial
Akira Kawai, Mikiya Ishihara, Tomoki Nakamura, et al.
Clinical Cancer Research (2023) Vol. 29, Iss. 24, pp. 5069-5078
Open Access | Times Cited: 10
Endothelial activation and damage as a common pathological substrate in different pathologies and cell therapy complications
Marta Palomo, Ana Belén Moreno‐Castaño, María Queralt Salas, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 9
Genetic Susceptibility in Endothelial Injury Syndromes after Hematopoietic Cell Transplantation and Other Cellular Therapies: Climbing a Steep Hill
Paschalis Evangelidis, Nikolaos Evangelidis, Panagiotis Kalmoukos, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 5, pp. 4787-4802
Open Access | Times Cited: 3
Chimeric antigen receptor T‐cell therapy toxicities
Uri Greenbaum, Partow Kebriaei, Samer A. Srour, et al.
British Journal of Clinical Pharmacology (2020) Vol. 87, Iss. 6, pp. 2414-2424
Open Access | Times Cited: 24
A Review of Cancer Immunotherapy Toxicity II: Adoptive Cellular Therapies, Kinase Inhibitors, Monoclonal Antibodies, and Oncolytic Viruses
Neeraj Chhabra, Joseph M. Kennedy
Journal of Medical Toxicology (2021) Vol. 18, Iss. 1, pp. 43-55
Open Access | Times Cited: 23
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity
Umberto Pensato, Giulia Amore, Roberto D’Angelo, et al.
Journal of Neurology (2021) Vol. 269, Iss. 2, pp. 609-615
Open Access | Times Cited: 21
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
Puri Ferreros, Isabel Trapero
Diseases (2022) Vol. 10, Iss. 3, pp. 41-41
Open Access | Times Cited: 15
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma
Avyakta Kallam, Julie M. Vose
Clinical Lymphoma Myeloma & Leukemia (2019) Vol. 19, Iss. 12, pp. 751-757
Closed Access | Times Cited: 23
Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization
Hans Urban, Eike Steidl, Elke Hattingen, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 13
Brain FDG‐PET findings in chimeric antigen receptor T‐cell therapy neurotoxicity for diffuse large B‐cell lymphoma
Silvia Morbelli, Massimiliano Gambella, Anna Maria Raiola, et al.
Journal of Neuroimaging (2023) Vol. 33, Iss. 5, pp. 825-836
Open Access | Times Cited: 7
CAR T-cell therapy for a relapsed/refractory acute B-cell lymphoblastic lymphoma patient in the context of Li-Fraumeni syndrome
Liting Chen, Bin Xu, Xiaolu Long, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000364-e000364
Open Access | Times Cited: 20
Rapid Progress in Immunotherapies for Multiple Myeloma: An Updated Comprehensive Review
Hiroko Nishida
Cancers (2021) Vol. 13, Iss. 11, pp. 2712-2712
Open Access | Times Cited: 16
Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Lymphomas: Current Status and Future Directions
Julio C. Chávez, Farah Yassine, José Sandoval-Sus, et al.
International Journal of Hematologic Oncology (2021) Vol. 10, Iss. 2
Open Access | Times Cited: 15
Neuroimaging findings in immune effector cell associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy
Adam H. Lapidus, Mary Ann Anderson, Simon J. Harrison, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2022) Vol. 63, Iss. 10, pp. 2364-2374
Closed Access | Times Cited: 9
Neurotoxicity Biology and Management
Husain Danish, Bianca Santomasso
The Cancer Journal (2021) Vol. 27, Iss. 2, pp. 126-133
Closed Access | Times Cited: 12
Chimeric antigen receptor T‐cell therapy in patients with neurologic comorbidities
Jeremy D. Rubinstein, Adam S. Nelson, Christa Krupski, et al.
Pediatric Blood & Cancer (2020) Vol. 67, Iss. 4
Closed Access | Times Cited: 12
Neuropsychological outcomes of patients with haematological malignancies undergoing chimeric antigen receptor T-cell therapy: protocol for a prospective study
Valeriya Kuznetsova, Harsh Oza, Hannah Rosenfeld, et al.
BMJ Neurology Open (2024) Vol. 6, Iss. 2, pp. e000800-e000800
Open Access | Times Cited: 1
Innovative cell therapies for systemic sclerosis: available evidence and new perspectives
Alain Lescoat, Monalisa Ghosh, Stephan Kadauke, et al.
Expert Review of Clinical Immunology (2024), pp. 1-15
Closed Access | Times Cited: 1
BCMA CAR-T Therapy Is Safe and Effective for Refractory/Relapsed Multiple Myeloma With Central Nervous System Involvement
Yiyun Wang, Cheng Zu, Xinyi Teng, et al.
Journal of Immunotherapy (2021) Vol. 45, Iss. 1, pp. 25-34
Closed Access | Times Cited: 10
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
Hashim Mann, Raymond L. Comenzo
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 799-813
Open Access | Times Cited: 7
Glioblastoma, an opportunity T cell trafficking could bring for the treatment
Mehdi Karimi‐Shahri, Malihe Khorramdel, Sara Zarei, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 10, pp. 9863-9875
Closed Access | Times Cited: 6

Scroll to top